Preventive therapy for cancer

The Lancet Oncology

Volumn 18, Issue 8, 2017, Pages e472-e482

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANASTROZOLE; ANTIESTROGEN; ARZOXIFENE; BETA CAROTENE; CELECOXIB; CURCUMIN; DUTASTERIDE; EXEMESTANE; FINASTERIDE; HEPATITIS B VACCINE; IBUPROFEN; LASOFOXIFENE; LYCOPENE; METFORMIN; ORAL CONTRACEPTIVE AGENT; POLYPHENOL DERIVATIVE; POMEGRANATE EXTRACT; RALOXIFENE; RESVERATROL; SELENIUM; SINECATECHINS; SULFORAPHANE; SULINDAC; TAMOXIFEN; TURMERIC; UNINDEXED DRUG; VITAMIN D; WART VIRUS VACCINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE DISTRIBUTION; AMBULATORY CARE; BRAIN HEMORRHAGE; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; COLON CANCER; COLON RESECTION; COLORECTAL CANCER; DIET THERAPY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOOD COMPOSITION; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC DISEASE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HYPERTENSION; INTRADUCTAL CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MASTECTOMY; MEDICAL INFORMATION; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NIGHT SWEAT; OVARIECTOMY; OVARY CANCER; POMEGRANATE; PRIORITY JOURNAL; PROSTATE CANCER; RED WINE; REVIEW; RISK FACTOR; STOMACH CANCER; SURGICAL APPROACH; TEA; THROMBOEMBOLISM; THROMBOSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; WART VIRUS; CHEMOPROPHYLAXIS; DIET; GENETICS; NEOPLASMS; PROPHYLACTIC MASTECTOMY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; ASPIRIN; CHEMOPREVENTION; COLECTOMY; CONTRACEPTIVES, ORAL; DIET; ESTROGEN ANTAGONISTS; HEPATITIS B VACCINES; HUMANS; NEOPLASMS; OVARIECTOMY; PAPILLOMAVIRUS VACCINES; PROPHYLACTIC MASTECTOMY; TAMOXIFEN;

EID: 85029722477     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30536-3     Document Type: Review

References (100)

1. Bisgaard, ML, Fenger, K, Bülow, S, Niebuhr, E, Mohr, J, Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3 (1994), 121–125.
2. Half, E, Bercovich, D, Rozen, P, Familial adenomatous polyposis. Orphanet J Rare Dis, 4, 2009, 22.
3. Mavaddat, N, Peock, S, Frost, D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105 (2013), 812–822.
4. Guillem, JG, Wood, WC, Moley, JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24 (2006), 4642–4660.
5. Ludwig, KK, Neuner, J, Butler, A, Geurts, JL, Kong, AL, Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg 212 (2016), 660–669.
6. Dubeau, L, The cell of origin of ovarian epithelial tumours. Lancet Oncol 9 (2008), 1191–1197.
7. Southey, MC, Goldgar, DE, Winqvist, R, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 53 (2016), 800–811.
8. Ault, KA, for the Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007), 1861–1868.
9. Paavonen, J, Naud, P, Salmerón, J, et al., for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009), 301–314.
10. Joura, EA, Giuliano, AR, Iversen, OE, et al., for the Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372 (2015), 711–723.
11. Chang, MH, You, SL, Chen, CJ, et al., for the Taiwan Hepatoma Study Group. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151 (2016), 472–480.
12. Fung, J, Lai, CL, Yuen, MF, Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect 15 (2009), 964–970.
13. Webster, DP, Klenerman, P, Dusheiko, GM, Hepatitis C. Lancet 385 (2015), 1124–1135.
14. Havrilesky, LJ, Moorman, PG, Lowery, WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 122 (2013), 139–147.
15. Cuzick, J, Sestak, I, Forbes, JF, et al., for the the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383 (2014), 1041–1048.
16. Rothwell, PM, Wilson, M, Elwin, CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376 (2010), 1741–1750.
17. Algra, AM, Rothwell, PM, Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13 (2012), 518–527.
18. Bosetti, C, Rosato, V, Gallus, S, Cuzick, J, La Vecchia, C, Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23 (2012), 1403–1415.
19. Cuzick, J, Sestak, I, Bonanni, B, et al., for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381 (2013), 1827–1834.
20. Martino, S, Cauley, JA, Barrett-Connor, E, et al., for the CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (2004), 1751–1761.
21. Barrett-Connor, E, Mosca, L, Collins, P, et al., for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006), 125–137.
22. Vogel, VG, Costantino, JP, Wickerham, DL, et al., for the National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (2006), 2727–2741.
23. LaCroix, AZ, Powles, T, Osborne, CK, et al., for the PEARL Investigators. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102 (2010), 1706–1715.
24. Powles, TJ, Diem, SJ, Fabian, CJ, et al. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat 134 (2012), 299–306.
25. Goss, PE, Ingle, JN, Alés-Martínez, JE, et al., for the NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364 (2011), 2381–2391.
26. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 57 (1988), 604–607.
27. Cuzick, J, Baum, M, Tamoxifen and contralateral breast cancer. Lancet, 2, 1985, 282.
28. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005), 1687–1717.
29. Powles, TJ, Ashley, S, Tidy, A, Smith, IE, Dowsett, M, Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (2007), 283–290.
30. Cuzick, J, Sestak, I, Cawthorn, S, et al., for the IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16 (2015), 67–75.
31. Fisher, B, Costantino, JP, Wickerham, DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (2005), 1652–1662.
32. Veronesi, U, Maisonneuve, P, Rotmensz, N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (2007), 727–737.
33. Cuzick, J, Sestak, I, Baum, M, et al., for the ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11 (2010), 1135–1141.
34. Sestak, I, Sapunar, F, Cuzick, J, Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 27 (2009), 4961–4965.
35. Spagnolo, F, Sestak, I, Howell, A, Forbes, JF, Cuzick, J, Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II Prevention trial. J Clin Oncol 34 (2016), 139–143.
36. Thorat, MA, Cuzick, J, Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol 30 (2015), 5–18.
37. Cuzick, J, Forbes, JF, Sestak, I, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99 (2007), 272–282.
38. Lee, O, Khan, SA, Novel routes for administering chemoprevention: local transdermal therapy to the breasts. Semin Oncol 43 (2016), 107–115.
39. Ettinger, B, Black, DM, Mitlak, BH, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282 (1999), 637–645.
40. Cauley, JA, Norton, L, Lippman, ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2001), 125–134.
41. Cummings, SR, Ensrud, K, Delmas, PD, et al., for the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362 (2010), 686–696.
42. Dowsett, M, Cuzick, J, Ingle, J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28 (2010), 509–518.
43. Cuzick, J, Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23 (2005), 1636–1643.
44. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. https://www.nice.org.uk/guidance/cg164/documents/short-version-of-addendum, November, 2016 (accessed June 15, 2017).
45. Cuzick, J, Thorat, MA, Bosetti, C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26 (2015), 47–57.
46. Baandrup, L, Kjaer, SK, Olsen, JH, Dehlendorff, C, Friis, S, Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann Oncol 26 (2015), 787–792.
47. Rothwell, PM, Fowkes, FG, Belch, JF, Ogawa, H, Warlow, CP, Meade, TW, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377 (2011), 31–41.
48. Rothwell, PM, Wilson, M, Price, JF, Belch, JF, Meade, TW, Mehta, Z, Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379 (2012), 1591–1601.
49. Cook, NR, Lee, IM, Zhang, SM, Moorthy, MV, Buring, JE, Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159 (2013), 77–85.
50. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989), 129–135.
51. Mills, EJ, Wu, P, Alberton, M, Kanters, S, Lanas, A, Lester, R, Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med 125 (2012), 560–567.
52. Chan, AT, Ogino, S, Fuchs, CS, Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302 (2009), 649–658.
53. Holmes, MD, Chen, WY, Li, L, Hertzmark, E, Spiegelman, D, Hankinson, SE, Aspirin intake and survival after breast cancer. J Clin Oncol 28 (2010), 1467–1472.
54. Langley, RE, Burdett, S, Tierney, JF, Cafferty, F, Parmar, MK, Venning, G, Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?. Br J Cancer 105 (2011), 1107–1113.
55. Chubak, J, Whitlock, EP, Williams, SB, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services task force. Ann Intern Med 164 (2016), 814–825.
56. Chan, AT, Giovannucci, EL, Meyerhardt, JA, Schernhammer, ES, Curhan, GC, Fuchs, CS, Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294 (2005), 914–923.
57. Shebl, FM, Hsing, AW, Park, Y, et al. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study. PLoS One, 9, 2014, e114633.
58. Bodmer, M, Meier, C, Krähenbühl, S, Jick, SS, Meier, CR, Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 (2010), 1304–1308.
59. Zhang, D, Bai, B, Xi, Y, Wang, T, Zhao, Y, Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecol Oncol 142 (2016), 368–377.
60. Golozar, A, Liu, S, Lin, JA, Peairs, K, Yeh, HC, Does metformin reduce cancer risks? Methodologic considerations. Curr Diab Rep, 16, 2016, 4.
61. Gandini, S, Puntoni, M, Heckman-Stoddard, BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7 (2014), 867–885.
62. Pollak, M, Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3 (2010), 1060–1065.
63. Naithani, R, Huma, LC, Moriarty, RM, McCormick, DL, Mehta, RG, Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15 (2008), 1044–1071.
64. Szabo, E, Biomarkers in phase I–II chemoprevention trials: lessons from the NCI experience. Ecancermedicalscience, 9, 2015, 599.
65. Negri, E, La Vecchia, C, Franceschi, S, D'Avanzo, B, Parazzini, F, Vegetable and fruit consumption and cancer risk. Int J Cancer 48 (1991), 350–354.
66. Lenzi, M, Fimognari, C, Hrelia, P, Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res 159 (2014), 207–223.
67. Mills, PK, Beeson, WL, Phillips, RL, Fraser, GE, Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64 (1989), 598–604.
68. Key, TJ, Appleby, PN, Travis, RC, et al., for the Endogenous Hormones Nutritional Biomarkers Prostate Cancer Collaborative Group. Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. Am J Clin Nutr 102 (2015), 1142–1157.
69. Zheng, J, Zhou, Y, Li, Y, Xu, DP, Li, S, Li, HB, Spices for prevention and treatment of cancers. Nutrients, 8, 2016, E495.
70. Devassy, JG, Nwachukwu, ID, Jones, PJ, Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev 73 (2015), 155–165.
71. Hackshaw-McGeagh, LE, Perry, RE, Leach, VA, et al. A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes Control 26 (2015), 1521–1550.
72. Vang, O, Ahmad, N, Baile, CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One, 6, 2011, e19881.
73. Gescher, A, Steward, WP, Brown, K, Resveratrol in the management of human cancer: how strong is the clinical evidence?. Ann N Y Acad Sci 1290 (2013), 12–20.
74. Li, MJ, Yin, YC, Wang, J, Jiang, YF, Green tea compounds in breast cancer prevention and treatment. World J Clin Oncol 5 (2014), 520–528.
75. Malik, A, Afaq, F, Sarfaraz, S, Adhami, VM, Syed, DN, Mukhtar, H, Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102 (2005), 14813–14818.
76. Bjelakovic, G, Gluud, LL, Nikolova, D, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev, 6, 2014 CD007469.
77. IARC Working Group Reports. Vitamin D and cancer, 2008, World Health Organization, Geneva, Switzerland.
78. Sporn, MB, Dunlop, NM, Newton, DL, Smith, JM, Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35 (1976), 1332–1338.
79. Peto, R, Doll, R, Buckley, JD, Sporn, MB, Can dietary beta-carotene materially reduce human cancer rates?. Nature 290 (1981), 201–208.
80. Blot, WJ, Li, JY, Taylor, PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population. J Natl Cancer Inst 85 (1993), 1483–1492.
81. Omenn, GS, Goodman, GE, Thornquist, MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (1996), 1150–1155.
82. Albanes, D, Heinonen, OP, Taylor, PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88 (1996), 1560–1570.
83. Druesne-Pecollo, N, Latino-Martel, P, Norat, T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 127 (2010), 172–184.
84. Klein, EA, Thompson, IM Jr, Tangen, CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306 (2011), 1549–1556.
85. Jiang, L, Yang, KH, Tian, JH, et al. Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: a meta-analysis of randomized controlled trials. Nutr Cancer 62 (2010), 719–727.
86. Pais, R, Dumitraşcu, DL, Do antioxidants prevent colorectal cancer? A meta-analysis. Rom J Intern Med 51 (2013), 152–163.
87. Bjelakovic, G, Nikolova, D, Gluud, LL, Simonetti, RG, Gluud, C, Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev, 3, 2012 CD007176.
88. Thompson, IM Jr, Goodman, PJ, Tangen, CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369 (2013), 603–610.
89. Andriole, GL, Bostwick, DG, Brawley, OW, et al., for the REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362 (2010), 1192–1202.
90. Pinsky, PF, Black, A, Grubb, R, et al. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer 119 (2013), 593–601.
91. Emberson, JR, Kearney, PM, Blackwell, L, et al., for the Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One, 7, 2012, e29849.
92. Parkin, DM, Boyd, L, Walker, LC, The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 105:suppl 2 (2011), S77–S81.
93. IARC Working Group on the Evaluation of Cancer-Preventive Strategies. Weight control and physical activity. Vainio, H, Biachini, F, (eds.) IARC handbook of cancer prevention, vol 6, 2002, IARC Press, Lyon, France, 60.
94. Thun, MJ, Jacobs, EJ, Patrono, C, The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9 (2012), 259–267.
95. Tyrer, J, Duffy, SW, Cuzick, J, A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23 (2004), 1111–1130.
96. Gail, MH, Brinton, LA, Byar, DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (1989), 1879–1886.
97. McCormack, VA, dos Santos Silva, I, Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15 (2006), 1159–1169.
98. Brentnall, AR, Evans, DG, Cuzick, J, Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK. Br J Cancer 110 (2014), 827–828.
99. Cuzick, J, Warwick, J, Pinney, E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103 (2011), 744–752.
100. Nyante, SJ, Sherman, ME, Pfeiffer, RM, et al. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst, 107, 2015, dju425.